#ASCO23 (Photo: Senior editor Max Gelman for Endpoints News)
June 5, 2023 08:00 AM EDT
R&D
Cell/Gene Tx

J&J takes vic­to­ry lap on its Carvyk­ti da­ta. But how many pa­tients will take it — and when? #AS­CO23

Max Gelman

Senior Editor

Lei Lei Wu

News Reporter

CHICA­GO — When Ley­la Shune first heard about a leaked ab­stract last month de­scrib­ing a dra­mat­ic 74% re­duc­tion in the risk of dis­ease pro­gres­sion or …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump says he'll sign or­der on 'most-fa­vored na­tion' drug price plans Mon­day

From deal to dis­as­ter: Drug­mak­ers face a changed Wash­ing­ton as Trump em­braces ‘most fa­vored na­tion’ prices

Rev­o­lu­tion’s KRAS drugs ap­pear com­pet­i­tive in sev­er­al lung can­cer set­tings

As­traZeneca re­ports Phase 3 win for Imfinzi; Roche to build new man­u­fac­tur­ing site in Chi­na

Lil­ly shuf­fles key ex­ec­u­tive po­si­tions; Mikael Dol­sten takes an­oth­er post-Pfiz­er as­sign­ment

sponsored

In one of the riski­est in­dus­tries — Biotech — a sure­fire way to neu­tral­ize some of that risk emerges

A service from the Financial Times